These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Immunological mechanisms in allergen-specific immunotherapy: impact on future trends in type-1 allergy management].
    Author: Ebner C.
    Journal: Wien Med Wochenschr; 1999; 149(14-15):438-41. PubMed ID: 10584289.
    Abstract:
    Specific immunotherapy (SIT) is the only treatment of Type-I allergy that leads to a modulation of the immune response to the eliciting allergen. The repeated administration of high doses of antigen induces a state of "antigen-specific non-responsiveness", i.e. immunologic tolerance to the injected antigen. Accordingly, during and after SIT the proliferative response of allergen-specific T lymphocytes in response to the administered antigen are significantly reduced. According to recent publications, this effect is due to the production of the immunosuppressive cytokine interleukin (IL)-10, which is induced during the treatment. On the other hand, a distinct change in the quality of the immune response to the injected allergen can be observed: the production of the IgE-inducing cytokine IL-4 by T helper cells decreases. Moreover, the release of other proinflammatory cytokines and inflammatory mediators is suppressed. Together, these events result in a marked decrease of symptoms during allergen exposure and reduced reactivity during challenge.
    [Abstract] [Full Text] [Related] [New Search]